US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Aquestive Therapeutics, Inc. - Common Stock
(NQ:
AQST
)
4.550
+0.110 (+2.48%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting
February 12, 2025
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference
February 04, 2025
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives
January 13, 2025
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
December 19, 2024
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States for the treatment of seizure clusters in patients ages 2 to 5
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside
↗
December 17, 2024
Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside.
Via
Benzinga
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
December 02, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
November 12, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 04, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College
October 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film
October 24, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
October 21, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
↗
September 30, 2024
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...
Via
Benzinga
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
September 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
September 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 22, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
August 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
July 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
July 23, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
June 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
↗
June 25, 2024
Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic reactions.
Via
Benzinga
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
June 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
June 18, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
June 03, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
May 28, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024
↗
May 07, 2024
AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 29, 2024
Via
Benzinga
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
